https://www.selleckchem.com/pr....oducts/Elesclomol.ht
8% vs. 33.8%), plaques (52.3% vs. 24.7%), and higher CACS (CACS 100, 63.6% vs. 26.5%) was assigned to statin therapy using the 2013 ACC/AHA guidelines (P .001 for all variables). The area under the curves of the pooled cohort equation of the new guidelines in detecting significant stenosis, plaques, and higher CACS were significantly higher than those of the Framingham risk calculator. Compared to the previous ATP III guidelines, the 2013 ACC/AHA guidelines were more sensitive in identifying subjects with subclinical coronar
Like
Comment
Share
